Reporting a fiscal first quarter which saw global underlying revenues rise around 1% despite the pandemic, Takeda Pharmaceutical Company Limited. says it “has not experienced a material effect” on its financial results so far, given a portfolio weighted towards chronic and serious disorders, although various aspects of operations have seen some impact.
Neuroscience saw some effect (underlying revenue in the sector was down 1%) as patients visited providers and were diagnosed less...
Welcome to Scrip
Create an account to read this article
Already a subscriber?